Once again, I applaud Jeff's wisdom!
I read that Zytiga has been replaced by Erleada.
Nubeca has special advantages if the cancer is caused by mutations. My doctor said that after Erleada, Nubeca will be the next step.
In other words, Nubeca is more effective than Erleada against mutation-induced cancer. I'm not a doctor; I read this information online and think I should ask my doctors if this is true.
And of course, the question arises, "For those with high Gleason scores and mutations, should they be prescribed Nubeca right away?" I'm taking Erleada, and I have Gleason score 9 and an ATM gene mutation.
Nubeca has been approved in our country since 2025. Do I really need to knock down my doctor's office door and force him to prescribe Nubeca?
Is there any real evidence that Nubeca works better against cancers with mutations? Thank you!
@denis76
Actually, Dennis Zytiga has not been replaced by Erleada. It is recommended that people go on Zytiga first, Because I can give them a longer time before they have to go on one of the lutamides. I know people that have successfully stayed on Zytiga for five years.
I got 2 1/2 years out of Zytiga, And almost 3 years out of Nubeqa. The extra 2 1/2 years was well worth it for a drug that has more side effects.
There is no mutation advantage to Nubeqa. I know dozens of people that have gone to Nubeqa Because it has fewer side effects than the other two lutamide drugs And doesn’t pass the blood brain barrier, So it doesn’t cause brain fog. Now ADT can cause brain fog, but the ARSI drugs cause even more.
Switching to Nubeqa Only gives you fewer side effects for a drug that pretty much acts the same as both apalutamide and Enzalutamide. That is the reason I know so many people that I’ve switched to it. It has nothing to do with mutations, It’s because it has fewer side effects.